WHY CHOOSE US
Diabetic Foot Ulcers: Beyond Standard Treatments
Chronic wounds are wounds that don’t heal within a normal timeframe. Common types include diabetic foot ulcers (DFU), venous leg ulcers (VLU), arterial wounds, and pressure ulcers. DFU and VLU often recur, with rates of 60–70%.
Standard diabetic foot ulcer treatment includes sharp debridement, offloading, and maintaining moisture. Still, many patients don’t achieve full healing, leaving a gap in effective care.
This clinical trial assesses the efficacy of an investigational treatment combined with standard care versus standard care alone. It evaluates whether the investigational treatment can help heal nonhealing DFUs and VLUs.
Enroll Now!
Interested in participating in a clinical trial?
"*" indicates required fields
Give Your Foot Ulcer a Chance to Heal Naturally
This clinical trial is testing human placental membrane (HPM) products to improve healing in nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The study is comparing four HPM products combined with standard care versus standard care alone. These treatments aim to create a protective healing environment, assist with tissue repair, and improve outcomes for patients with chronic wounds.
Patients experiencing diabetic foot ulcer symptoms may access this potential new treatment and help advance research by participating.
Eligibility Criteria
Age
18 Years and older
Location
Alexandria, LA
Gender
Both
Status
Recruiting
Condition
Diabetic Foot Ulcer
15
Length of
Study Treatment
7
Number of
Study Visits
GET STARTED
Why This Clinical Trial Matters
Chronic diabetic foot ulcers can severely affect mobility, daily life, and overall health, and many wounds don’t heal with standard care alone. This clinical trial explores potential new diabetic foot ulcer treatment using human placental membrane products, which support natural healing, protect tissues, and improve recovery. Participants gain access to advanced treatment possibilities and help research that could transform care for others.
Innovative Therapies for Chronic DFUs and VLUs
Diabetes affects over 500 million people worldwide, and type 2 diabetes is the most common form. Many patients develop diabetic foot ulcers (DFUs) due to pressure, friction, or injuries, which reduce quality of life and are costly to treat. Access to advanced care can be limited, making effective diabetic foot ulcer treatment essential.
Venous leg ulcers (VLUs) also affect millions, with high recurrence rates and treatment costs. Risk factors include obesity, noncompliance with therapy, and prior vein issues. This clinical study evaluates whether an investigational treatment combined with standard care, compared to standard care alone, can improve healing for patients with diabetic foot ulcer symptoms and nonhealing VLUs, offering hope for better outcomes.
ASK
Frequently Asked
Questions
What is this clinical trial about?
This trial is testing human placental membrane (HPM) products to improve healing in nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). It compares four HPM products combined with standard care versus standard care alone.
Who can participate in this trial?
Adults aged 18 years and older, of any gender, with diabetic foot ulcers can participate. The trial is currently recruiting in Alexandria, LA.
What treatments will participants receive?
Participants may receive one of the four HPM products along with standard care or standard care alone. The investigational treatments are designed to support healing, protect tissue, and improve recovery.
Why is this trial important?
Many chronic DFUs and VLUs do not heal with standard care alone, affecting mobility, quality of life, and overall health. This clinical trial explores potential new diabetic foot ulcer treatment options that may improve healing and help advance care for others.
How can I join the trial?
Patients with diabetic foot ulcer symptoms can contact the trial team to see if they qualify. Participation includes expert medical monitoring throughout the study and may provide access to potential new treatment options.
